NCT01869192View on ClinicalTrials.gov

Phase II Trial for Large ER-Negative Breast Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 5, 2003

Primary Completion Date

December 18, 2009

Study Completion Date

August 21, 2010

Conditions
Malignant Neoplasm of Female Breast
Interventions
DRUG

Epirubicin

Epirubicin 90 mg/m2 d1 q3w

DRUG

Cyclophosphamide

Cyclophosphamide 600 mg/m2 d1 q3w

DRUG

Docetaxel

Docetaxel 75 mg/m2 d1 q3w

DRUG

Capecitabine

Capecitabine 1000 mg/m2/dose bid x 14d q3w

RADIATION

Radiation Therapy

Standard dosing, fields depending on clinical findings

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT01869192 - Phase II Trial for Large ER-Negative Breast Cancers | Biotech Hunter | Biotech Hunter